Crystalline form of a SHP2 inhibitor
AssigneePfizer Inc.
InventorsKatie Keaton Brown, Aaron Keith Goodwin
Life of this patent
Estimating the term…
Abstract
This Invention relates to a hemihydrate crystalline form of (S)-1′-(6-((2-amino-3-chloropyridin-4-yl)thio)-1,2,4-triazin-3-yl)-1,3-dihydrospiro[indene-2,4′-piperidin]-1-amine free base (Form 1). The invention also relates to pharmaceutical compositions comprising this crystalline form, and to methods of using the crystalline form and such compositions for the treatment of abnormal cell growth, such as cancer, in a mammal.
Claims14
A hemihydrate crystalline form of(S)-1′-(6-((2-amino-3-chloropyridin-4-yl)thio)-1,2,4-triazin-3-yl)-1,3-dihydrospiro[indene-2,4′-piperidin]-1-amine free base characterized by a PXRD pattern comprising characterizing peaks at 2θ values of 10.9, 14.0, 15.4, and 16.0±0.2° 2θ.
Dependencies are inferred from the claim text.